Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics of Disulfiram for Cocaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV diagnosis criteria for opioid dependence, as determined by documentation of prior treatment for addiction; signs of withdrawal; self-reported history of dependence for at least 1 year; and a positive urine test for opioids~* Meets DSM-IV diagnosis criteria for cocaine dependence, as determined by self-reported use of cocaine at least once weekly for at least 1 month prior to study entry; a positive urine test for cocaine; and a score greater than 3 on the Severity Dependence Scale~* If female, willing to use contraception throughout the study~Exclusion criteria:~* Meets DSM-IV diagnosis criteria for dependence on any drugs other than opiates, cocaine, or tobacco~* Current major psychiatric illness, including schizophrenia, bipolar disorder, or other psychotic disorder~* Current suicidal or homicidal ideation~* Current use of a prescribed psychotropic medication that cannot be discontinued~* History of or current major medical illness, including major heart, kidney, endocrine, or liver disorder; abnormal liver function (SGOT or SGPT levels three times greater than normal);~* High risk factor for heart disease, seizure disorders, or any illness for which disulfiram or methadone treatment would be inadvisable~* Currently taking metronidazole or clotrimazole~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Disulfiram, Methadone (w/lactose) & CBT (Type: EXPERIMENTAL): Participants are randomly assigned to receive a daily dose of 250 mg of disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
- Placebo, Methadone (w/lactose) & CBT (Type: ACTIVE_COMPARATOR): Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.

Based on this trial design, predict the completion outcome and termination type (if applicable).